Cargando…
Severe relapse of anti-NMDA receptor encephalitis 5 years after initial symptom onset
Anti-NMDAR encephalitis is characterized by abnormal behavior, cognitive dysfunction, seizures, disturbance of consciousness, central hypoventilation, and movement disorders, with a tendency to occur in younger women. Immunotherapy and tumor removal, where applicable, are effective for this disorder...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661405/ https://www.ncbi.nlm.nih.gov/pubmed/31384674 http://dx.doi.org/10.1016/j.ensci.2019.100199 |
_version_ | 1783439443743473664 |
---|---|
author | Nakajima, Hideto Unoda, Kiichi Hara, Makoto |
author_facet | Nakajima, Hideto Unoda, Kiichi Hara, Makoto |
author_sort | Nakajima, Hideto |
collection | PubMed |
description | Anti-NMDAR encephalitis is characterized by abnormal behavior, cognitive dysfunction, seizures, disturbance of consciousness, central hypoventilation, and movement disorders, with a tendency to occur in younger women. Immunotherapy and tumor removal, where applicable, are effective for this disorder. However, previous papers have shown neurological relapse in 12–24% of cases. We present a case of anti-NMDAR encephalitis relapse 5 years after the initial episode. Although the relapse was much more severe than the initial episode, she recovered with aggressive therapy using first- and second-line immunotherapies. Anti- NMDAR encephalitis could relapse with a more severe clinical course after several years. Aggressive immunotherapy including cyclophosphamide must be necessary even for recurrent cases of anti-NMDAR encephalitis. |
format | Online Article Text |
id | pubmed-6661405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-66614052019-08-05 Severe relapse of anti-NMDA receptor encephalitis 5 years after initial symptom onset Nakajima, Hideto Unoda, Kiichi Hara, Makoto eNeurologicalSci Letters to the Editor Anti-NMDAR encephalitis is characterized by abnormal behavior, cognitive dysfunction, seizures, disturbance of consciousness, central hypoventilation, and movement disorders, with a tendency to occur in younger women. Immunotherapy and tumor removal, where applicable, are effective for this disorder. However, previous papers have shown neurological relapse in 12–24% of cases. We present a case of anti-NMDAR encephalitis relapse 5 years after the initial episode. Although the relapse was much more severe than the initial episode, she recovered with aggressive therapy using first- and second-line immunotherapies. Anti- NMDAR encephalitis could relapse with a more severe clinical course after several years. Aggressive immunotherapy including cyclophosphamide must be necessary even for recurrent cases of anti-NMDAR encephalitis. Elsevier 2019-07-19 /pmc/articles/PMC6661405/ /pubmed/31384674 http://dx.doi.org/10.1016/j.ensci.2019.100199 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Letters to the Editor Nakajima, Hideto Unoda, Kiichi Hara, Makoto Severe relapse of anti-NMDA receptor encephalitis 5 years after initial symptom onset |
title | Severe relapse of anti-NMDA receptor encephalitis 5 years after initial symptom onset |
title_full | Severe relapse of anti-NMDA receptor encephalitis 5 years after initial symptom onset |
title_fullStr | Severe relapse of anti-NMDA receptor encephalitis 5 years after initial symptom onset |
title_full_unstemmed | Severe relapse of anti-NMDA receptor encephalitis 5 years after initial symptom onset |
title_short | Severe relapse of anti-NMDA receptor encephalitis 5 years after initial symptom onset |
title_sort | severe relapse of anti-nmda receptor encephalitis 5 years after initial symptom onset |
topic | Letters to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661405/ https://www.ncbi.nlm.nih.gov/pubmed/31384674 http://dx.doi.org/10.1016/j.ensci.2019.100199 |
work_keys_str_mv | AT nakajimahideto severerelapseofantinmdareceptorencephalitis5yearsafterinitialsymptomonset AT unodakiichi severerelapseofantinmdareceptorencephalitis5yearsafterinitialsymptomonset AT haramakoto severerelapseofantinmdareceptorencephalitis5yearsafterinitialsymptomonset |